Pharmaron Beijing (300759) Fundamentals 2026 — P/E 41.4x, Revenue Analysis | SniperIQ
Pharmaron Beijing (300759) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥58.7B, trading at ¥39.76 on the SHZ. This SniperIQ fundamentals page covers Pharmaron Beijing's valuation (P/E 41.4x, P/B 4.4x), profitability (net margin 11.7%), revenue (¥14.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pharmaron Beijing's market cap?
Pharmaron Beijing (300759) has a market capitalization of approximately ¥58.7B, trading at ¥39.76 on the SHZ. Market cap moves with the live share price.
What is Pharmaron Beijing's P/E ratio?
Pharmaron Beijing's trailing twelve-month P/E ratio is 41.4x, with a price-to-book (P/B) of 4.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pharmaron Beijing?
Pharmaron Beijing runs a net profit margin of 11.7%, a gross margin of 34.1%, and an operating margin of 13.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Pharmaron Beijing generate?
Pharmaron Beijing reported revenue of ¥14.1B for fiscal year 2025, with net income of ¥1.7B and earnings per share (EPS) of 0.94. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Pharmaron Beijing pay a dividend?
Pharmaron Beijing offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Pharmaron Beijing financially healthy?
Pharmaron Beijing carries a debt-to-equity ratio of 0.43x and a current ratio of 1.08x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pharmaron Beijing a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pharmaron Beijing (300759) the key facts are: market cap ¥58.7B, P/E 41.4x, revenue ¥14.1B, 52-week range 21.01-42. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pharmaron Beijing's full fundamentals live
Get Pharmaron Beijing's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.